Scaling up Antiretroviral Therapy in Resource Limited Settings : Guidelines for a Public Health Approach: XV. Monitoring antiretroviral therapy: Annex 6. Characteristics of NNRTI-, triple NsRTI- and PI-based regimens in special populations

Scaling up Antiretroviral Therapy in Resource Limited Settings : Guidelines for a Public Health Approach
(2002; 163 pages) [French]

Table of Contents

	Abbreviations
	Preface
	Summary
	I. Introduction
	II. Objectives of the document
	III. Background and purpose
	IV. Approach to antiretroviral therapy
	V. When to start antiretroviral therapy in adults and adolescents
	VI. Recommended first-line regimens for adults and adolescents
	VII. When to change therapy in adults and adolescents
	VIII. Recommended second-line regimens in adults and adolescents
	IX. Drug resistance
	X. Antiretroviral therapy in women, with specific reference to pregnancy
	XI. Infants and children
	XII. Tuberculosis and other HIV-related conditions
	XIII. Injecting drug users
	XIV. Drug adherence
	XV. Monitoring antiretroviral therapy
		Annex 1. WHO staging system for HIV infection and disease in adults and adolescents
		Annex 2. WHO staging system for HIV infection and disease in children
		Annex 3. Characteristics of NNRTI-based regimens
		Annex 4. Characteristics of triple NsRTI-based regimens
		Annex 5. Characteristics of PI-based regimens
		Annex 6. Characteristics of NNRTI-, triple NsRTI- and PI-based regimens in special populations
		Annex 7. Antiretroviral dosage regimens for adults and adolescents
		Annex 8a. Antiretroviral drug interactions
		Annex 8b. Drug interactions between non-nucleoside reverse transcriptase inhibitors and protease inhibitors
		Annex 8c. Drug interactions involving non-nucleoside reverse transcriptase inhibitors and protease inhibitors of relevance to poor countries
		Annex 9. Choice of antiretroviral drugs in HIV-infected pregnant women
		Annex 10. Summary of paediatric drug formulations and doses
		Annex 11a. Antiretroviral drug toxicity
		Annex 11b. Monitoring and management of antiretroviral drug toxicity
	References
	Interim WHO Antiretroviral Treatment Working Group, Geneva, 19-20 november 2001
	WHO International Consultative Meeting on HIV/AIDS Antiretroviral Therapy, 22-23 May 2001, Geneva

Annex 6. Characteristics of NNRTI-, triple NsRTI- and PI-based regimens in special populations

	Pregnant women	Children<3 years	Children3 years	Tuberculosis coinfected	Injecting drug users	Group O infected, HIV-2 infected
NNRTI-based regimens
ZDV/3TC/EFZ	-	-	++++	+++	++	-
d4T/3TC/EFZ	-	-	+++	+++	++	-
d4T/ddI/EFZ	-	-	+++	-	++	-
ZDV/ddI/EFZ	-	-	+++	+++	++	-
ZDV/3TC/NVP	++++	++++	++++	+	++	-
d4T/3TC/NVP	+++	+++	+++	+	++	-
d4T/ddI/NVP	-	+++	+++	-	+	--
ZDV/ddI/NVP	++++	+++	+++	+	++	++++
Triple NsRTI- based regimens
ZDV/3TC/ABC	++	+++	++++	++++	++++	++++
d4T/3TC/ABC	++	+++	++++	++++	++++	++++
d4T/ddI/ABC	-	++	+++	++	++	++++
ZDV/ddI/ABC	++	++	+++	++	+++	++++
PI-based
ZDV/3TC/NFV	++++	++	+++	-	+++	++++
d4T/3TC/NFV	+++	++	+++	-	+++	++++
d4T/ddI/NFV	-	++	+++	-	+++	++++
ZDV/ddI/NFV	+++	++	+++	-	+++	++++
ZDV/3TC/IDV/r	++	-	+	-	+++	++++
d4T/3TC/IDV/r	++	-	+	-	+++	++++
d4T/ddI/IDV/r	-	-	+	-	++	++++
ZDV/ddI/IDV/r	++	-	+	-	++	++++
ZDV/3TC/LPV/r	+	++	+++	-	+++	++++
d4T/3TC/LPV/r	+	++	+++	-	+++	++++
d4T/ddI/LPV/r	-	++	+++	-	++	++++
ZDV/ddI/LPV/r	+	++	+++	-	++	++++
ZDV/3TC/SQV/r	++++	-	+	++	+++	++++
d4T/3TC/SQV/r	+++	-	+	++	+++	++++
d4T/ddI/SQV/r	-	-	+	-	++	++++
ZDV/ddI/SQV/r	+++	-		+	++	++++

^aKey to table: ++++ = most favorable; + = least favorable or information very limited;- = contraindicated or risks may outweigh benefits.